Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2004

Blons Hélène, Gad Sophie, Zinzindohoué Franck, Manière Isabelle, Beauregard Janie, Tregouet David, Brasnu Daniel, Beaune Philippe, Laccourreye Ollivier, Laurent-Puig Pierre

Abstract excerpt

PURPOSE: Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy. In an attempt to optimize therapeutics, the identification of molecular markers linked to response to chemotherapy remains important. Recently, the involvement of metalloproteinases in resistance to chemotherapy was suggested through their interaction with the Fas/Fas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fas Ligand Protein

Share to fas Receptor

Share to Fluorouracil

Share to Matrix Metalloproteinase 1

Share to Matrix Metalloproteinase 3

Share to Matrix Metalloproteinase 7

Source

Identifiers

PMID: 15102660
DOI: 10.1158/1078-0432.ccr-1116-03

Genes

MMP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.PMID 15102660Read ↗

Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.Semantic proximity Read ↗

The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer.Semantic proximity Read ↗

Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk.Semantic proximity Read ↗

Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions.Semantic proximity Read ↗

A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer.Semantic proximity Read ↗

Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas.Semantic proximity Read ↗

Matrix metalloproteinase 1, 3, and 9 polymorphisms and esophageal squamous cell carcinoma risk.Semantic proximity Read ↗

Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer.Semantic proximity Read ↗

A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma.Semantic proximity Read ↗

Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival.Semantic proximity Read ↗

A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.